Dr Richard Wyse named in His Majesty The King’s New Year’s Honours List
Dr. Richard Wyse, Cure Parkinson’s Director of Clinical Development, has been recognised with a prestigious inclusion in His Majesty The King’s New Year’s Honours List, for services to medicine in Parkinson's disease.
Learn more
GDNF – A new chapter
We welcome the news of further investment in GDNF (Glial Cell-Line Derived Neurotrophic Factor) by Parkinson’s UK.
‘AskBio’ acquires BNB and GDNF gene therapy trials
BNB and AskBio have joined forces to expand a gene therapy programme for Parkinson’s
Herantis Pharma: Phase 1/2 CDNF topline results
We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint of safety and tolerability. In pre-clinical studies, CDNF has…
GDNF and cell transplantation: dual therapies for Parkinson’s
Parkinson’s is a complex condition and it is becoming increasingly clear that the future of disease-modifying therapies for Parkinson’s will rely on the use of multiple treatment approaches, as opposed to a single therapy. Scientists in Australia have recently published pre-clinical research exploring this idea…
GDNF trial results published
Results from a pioneering clinical trials programme that delivered an experimental treatment directly into the brain of people with Parkinson’s offer hope that it may be possible to restore damaged neurons. The findings from these ground-breaking trials are published today in Brain and the Journal of Parkinson’s Disease. …